He also penned a manuscript in 1987 that started with this claim: During the last decade and especially in the last few years scientific evidence has been gradually emerging, and now indicates that smoking may in fact provide a net contribution in the prevention of certain diseases and in extending life expectancy. After reviewing the manuscript, another paid consultant, Peter Lee, wrote a confidential letter to a corporate officer at British-American Tobacco, saying, I think the paper is pretty valueless, partly as it is completely unbalanced, partly as the (many) wild claims made are not substantiated by detailed evidence. A critique by a BAT attorney suggests that the company closely monitored the work of its consultants: It obviously needs to be honed into a first-class scientific paper
idle, lazy, indolent, Page 1660 and 1661: nosedive or tailspin: Prices on the Page 1662 and 1663: 3 elegant, chic, fashionable, styli Page 1664 and 1665: pate shone in the moonlight
The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Downside RiskBritish American Tobacco has a consensus price target of $51.00, representing about 16.2% downside from its current price of $60.89.Amount of Analyst CoverageBritish American Tobacco has only been the subject of 4 research reports in the past 90 days.Read more about British American Tobacco's stock forecast and price target
11: 00902-2024 [DOI: 10.1183/23120541.00902-2024]
Join our newsletter for blog updates, beekeeping videos, sales and contests.